Experimental hepatitis b treatment trial halted before starting

NCT ID NCT02349126

Summary

This study aimed to test whether adding an experimental drug called ARC-520 to standard Hepatitis B medications could better control the virus. It was designed for adults already taking daily antiviral pills. The trial was withdrawn by the sponsor before any patients were enrolled.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site 1

    Melbourne, Victoria, 3004, Australia

Conditions

Explore the condition pages connected to this study.